Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2018.05.009
Abstract: Background Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. Case We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease,… read more here.
Keywords: treatment resistant; uterine serous; treatment; sacituzumab govitecan ... See more keywords
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2019.1654378
Abstract: ABSTRACT Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies… read more here.
Keywords: cancer; sacituzumab govitecan; triple negative; breast cancer ... See more keywords
Abstract 2171: A multivariate biomarker predicts sacituzumab govitecan response in solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2171
Abstract: Despite the recent clinical success of antibody drug conjugates (ADC) in oncology, predictive biomarkers are lacking, potentially limiting their impact. Herein, we evaluated the ability of candidate biomarkers alone and in combination to predict objective… read more here.
Keywords: biomarker; tumor; multivariate biomarker; expression ... See more keywords
Abstract 4895: Introduction of a platform for preclinical profiling of drug conjugates: a case study with sacituzumab govitecan
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4895
Abstract: Drug-conjugates are an emerging class of anticancer agents combining the cytotoxic activity of highly potent chemotherapeutic agents with the target specificity of an antibody, a small molecule or a peptide ligand directed against a cancer-associated… read more here.
Keywords: platform; drug conjugates; biology; sacituzumab govitecan ... See more keywords
Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct268
Abstract: Despite provocative preclinical results, dose-limiting toxicities have precluded rational combinations of cytotoxic chemotherapies that increase DNA damage with DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted delivery of cytotoxic chemotherapy might enable tolerable and… read more here.
Keywords: combination; sacituzumab govitecan; replication stress; chemotherapy ... See more keywords
Abstract B016: Liquid biopsy biomarker analysis of a phase II trial of sacituzumab govitecan in castrate resistant metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.prca2023-b016
Abstract: Background: Sacituzumab Govitecan (SG) is an antibody-drug conjugate targeting Trop-2 and has been approved for use in breast and bladder cancers. Trop-2 has been shown to be overexpressed in multiple solid tumors including prostate cancer.… read more here.
Keywords: prostate cancer; trial; sacituzumab govitecan; analysis ... See more keywords
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-21-0702
Abstract: Sacituzumab Govitecan (SG), the first antibody drug conjugate (ADC) approved for triple-negative breast cancer (TNBC), incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We sought to identify mechanisms of SG resistance… read more here.
Keywords: negative breast; cancer; resistance; sacituzumab govitecan ... See more keywords
Role of sacituzumab govitecan in solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221092359
Abstract: Objective To evaluate the antibody-drug conjugate- sacituzumab govitecan, its pharmacological properties, toxicity, data supporting efficacy against a wide variety of solid tumors beyond breast cancer, and potential future uses. Data Sources Articles in MEDLINE/PubMed databases… read more here.
Keywords: breast cancer; sacituzumab govitecan; antibody drug; solid tumors ... See more keywords
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
Sign Up to like & getrecommendations! Published in 2020 at "Oncotarget"
DOI: 10.18632/oncotarget.27342
Abstract: Background Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We… read more here.
Keywords: cell lines; sacituzumab govitecan; uterine ovarian; ovarian carcinosarcomas ... See more keywords
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Future oncology"
DOI: 10.2217/fon-2021-0868
Abstract: Sacituzumab Govitecan (also known by the brand name TRODELVY®) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short. Metastatic breast cancer means the breast cancer has spread to other… read more here.
Keywords: sacituzumab govitecan; study; breast cancer; cancer ... See more keywords
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0407
Abstract: Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor… read more here.
Keywords: new antibody; sacituzumab govitecan; drug conjugate; antibody drug ... See more keywords